Sugammadex Fresenius Kabi

Country: Европска Унија

Језик: Енглески

Извор: EMA (European Medicines Agency)

Купи Сада

Активни састојак:

sugammadex sodium

Доступно од:

Fresenius Kabi Deutschland GmbH

АТЦ код:

V03AB35

INN (Међународно име):

sugammadex

Терапеутска група:

All other therapeutic products

Терапеутска област:

Neuromuscular Blockade

Терапеутске индикације:

Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Статус ауторизације:

Authorised

Датум одобрења:

2022-07-15

Информативни летак

                                30
B.
PACKAGE LEAFLET
31
PACKAGE LEAFLET: INFORMATION FOR THE USER
SUGAMMADEX FRESENIUS KABI 100
MG/ML SOLUTION FOR INJECTION
sugammadex
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE
BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have further questions, ask your anaesthetist or doctor.
•
If you get any side effects, talk to your anaesthetist or other
doctor. This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Sugammadex Fresenius Kabi is and what it is used for
2.
What you need to know before Sugammadex Fresenius Kabi is given
3.
How Sugammadex Fresenius Kabi is given
4.
Possible side effects
5.
How to store Sugammadex Fresenius Kabi
6.
Contents of the pack and other information
1.
WHAT SUGAMMADEX FRESENIUS KABI IS AND WHAT IT IS USED FOR
WHAT SUGAMMADEX FRESENIUS KABI IS
Sugammadex Fresenius Kabi contains the active substance sugammadex.
Sugammadex is considered
to be a
_selective relaxant binding agent _
since it only works with specific muscle relaxants,
rocuronium bromide or vecuronium bromide.
WHAT SUGAMMADEX FRESENIUS KABI IS USED FOR
When you have some types of operations, your muscles must be
completely relaxed. This makes it
easier for the surgeon to do the operation. For this, the general
anaesthetic you are given includes
medicines to make your muscles relax. These are called
_muscle relaxants_
, and examples include
rocuronium bromide and vecuronium bromide. Because these medicines
also make your breathing
muscles relax, you need help to breathe (artificial ventilation)
during and after your operation until you
can breathe on your own again.
Sugammadex is used to speed up the recovery of your muscles after an
operation to allow you to breathe
on your own again earlier. It does this by combining with the
rocuronium bromide or vecuronium
bromide in your body. It can be used in adults whenever rocuronium
bromide or vecuronium bromide is
used and in 
                                
                                Прочитајте комплетан документ
                                
                            

Карактеристике производа

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Sugammadex Fresenius Kabi100 mg/mL solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
1 mL contains sugammadex sodium equivalent to 100 mg sugammadex.
Each vial of 1 mL contains sugammadex sodium equivalent to 100 mg
sugammadex.
Each vial of 2 mL contains sugammadex sodium equivalent to 200 mg
sugammadex.
Each vial of 5 mL contains sugammadex sodium equivalent to 500 mg
sugammadex.
Excipient(s) with known effect
Contains up to 9.7 mg/mL sodium (see section 4.4).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection (injection).
Clear and colourless to slightly yellow solution, free from visible
particles.
The pH is between 7 and 8 and osmolality is between 300 and 500
mOsm/kg.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Reversal of neuromuscular blockade induced by rocuronium or vecuronium
in adults.
For the paediatric population: sugammadex is only recommended for
routine reversal of rocuronium
induced blockade in children and adolescents aged 2 to 17 years.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
Sugammadex should only be administered by, or under the supervision of
an anaesthetist.
The use of an appropriate neuromuscular monitoring technique is
recommended to monitor the recovery
of neuromuscular blockade (see section 4.4).
The recommended dose of sugammadex depends on the level of
neuromuscular blockade to be reversed.
The recommended dose does not depend on the anaesthetic regimen.
Sugammadex can be used to reverse different levels of rocuronium or
vecuronium induced
neuromuscular blockade:
_Adults _
_ _
_Routine reversal: _
A dose of 4 mg/kg sugammadex is recommended if recovery has reached at
least 1-2 post-tetanic counts
(PTC) following rocuronium or vecuronium induced blockade. Median time
to recovery of the T
4
/T
1
ratio to 0.9 is around 3 minutes (see section 5.1).
3
A dose of 2 mg/kg sugammadex is recommended, if spontaneous recovery
has occurred
                                
                                Прочитајте комплетан документ
                                
                            

Документи на другим језицима

Информативни летак Информативни летак Бугарски 21-07-2022
Информативни летак Информативни летак Шпански 21-07-2022
Информативни летак Информативни летак Чешки 21-07-2022
Информативни летак Информативни летак Дански 21-07-2022
Информативни летак Информативни летак Немачки 21-07-2022
Информативни летак Информативни летак Естонски 21-07-2022
Информативни летак Информативни летак Грчки 21-07-2022
Информативни летак Информативни летак Француски 21-07-2022
Карактеристике производа Карактеристике производа Француски 21-07-2022
Информативни летак Информативни летак Италијански 21-07-2022
Карактеристике производа Карактеристике производа Италијански 21-07-2022
Извештај о процени јавности Извештај о процени јавности Италијански 21-07-2022
Информативни летак Информативни летак Летонски 21-07-2022
Информативни летак Информативни летак Литвански 21-07-2022
Карактеристике производа Карактеристике производа Литвански 21-07-2022
Информативни летак Информативни летак Мађарски 21-07-2022
Информативни летак Информативни летак Мелтешки 21-07-2022
Информативни летак Информативни летак Холандски 21-07-2022
Карактеристике производа Карактеристике производа Холандски 21-07-2022
Информативни летак Информативни летак Пољски 21-07-2022
Информативни летак Информативни летак Португалски 21-07-2022
Карактеристике производа Карактеристике производа Португалски 21-07-2022
Извештај о процени јавности Извештај о процени јавности Португалски 21-07-2022
Информативни летак Информативни летак Румунски 21-07-2022
Информативни летак Информативни летак Словачки 21-07-2022
Информативни летак Информативни летак Словеначки 21-07-2022
Карактеристике производа Карактеристике производа Словеначки 21-07-2022
Извештај о процени јавности Извештај о процени јавности Словеначки 21-07-2022
Информативни летак Информативни летак Фински 21-07-2022
Информативни летак Информативни летак Шведски 21-07-2022
Информативни летак Информативни летак Норвешки 21-07-2022
Информативни летак Информативни летак Исландски 21-07-2022
Карактеристике производа Карактеристике производа Исландски 21-07-2022
Информативни летак Информативни летак Хрватски 21-07-2022

Обавештења о претрази у вези са овим производом

Погледајте историју докумената